Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Effects of Different Sled Loads on Sprint and Neuromuscular Performance in Young Male Football Players: An 8-Week Periodized Field Study

NCT07797920 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-09-05
Last updated
2026-09-01

Condition(s) studied

Athletic PerformanceNeuromuscular Adaptations

Investigational drug(s) / intervention(s)

Resisted Sled Sprint Training

Resisted Sled Sprint Training: An 8-week periodized resisted sprint training protocol using weighted sleds. Sessions are performed twice weekly over a 15-meter sprint distance, immediately following a standardized warm-up. Participants are assigned to sled towing loads equivalent to 10%, 15%, or 20% of their individual body weight (BW). Training volume progresses systematically from 2 sets of 3 repetitions (Weeks 1-2) to 3 sets of 4 repetitions (Weeks 7-8) with 2 minutes of inter-repetition rest and 3 minutes of inter-set rest.

Study summary

The purpose of this 8-week periodized field study is to investigate and compare the acute and chronic effects of three different sled towing loads (10%, 15%, and 20% of body weight \[BW\]) on sprint performance (5m, 10m, 15m) and neuromuscular characteristics (Squat Jump \[SJ\], Countermovement Jump \[CMJ\], Drop Jump \[DJ\], and Reactive Strength Index \[RSI\]) in trained male youth football players aged 13-14 years. While all other training variables (distance, frequency, volume, and rest intervals) are standardized, this study aims to identify the optimal sled load that enhances acceleration and horizontal force production without compromising running mechanics during a critical pediatric athletic development window.

Eligibility

Sex
MALE
Min age
13 Years
Max age
14 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Male football players aged chronologically between 13 and 14 years. * Minimum of 2 years of active, licensed competitive football experience in a club or academy. * Regular attendance at scheduled team training sessions. * Written Informed Consent/Assent signed by both the participant (Child Assent Form) and parent/legal guardian (Parental Consent Form). * Free of severe lower-limb musculoskeletal injuries (e.g., ligament tears, fractures, meniscus injuries) in the past 6 months. Exclusion Criteria: * Chronological age \<13 or \>14 years. * Presence of chronic, cardiovascular, metabolic, or respiratory conditions (e.g., asthma) that pose risks during high-intensity maximal exercise. * Regular use of performance-enhancing supplements or medications affecting physiological and neuromuscular responses. * Absence from more than 10% of prescribed sled training sessions (2 or more sessions out of 16). * Failure to complete pre- or post-intervention performance testing batteries, or failure to demonstrate maximal effort during testing. * Concurrent participation in external individual strength, speed, or fitness programs outside the football academy.

Primary outcome measure(s)

  • Linear Sprint Performance (5m, 10m, and 15m Sprint Times) — Baseline (Pre-test) and 8 weeks (Post-test)
    Linear sprint performance measured over 5 meters (acceleration), 10 meters, and 15 meters using a high-precision wireless photocell timing system. Times are measured in seconds (s), where lower values indicate better sprint performance.
  • Squat Jump (SJ) Height — Baseline (Pre-test) and 8 weeks (Post-test)
    Lower-limb concentric explosive power output measured via Squat Jump test on a digital contact mat/force platform. Surcharge from arm swing is isolated by keeping hands on hips. Jump height is measured in centimeters (cm), where higher values indicate greater explosive power output.
  • Countermovement Jump (CMJ) Height — Baseline (Pre-test) and 8 weeks (Post-test)
    Stretch-shortening cycle (SSC) performance and lower-limb reactive power measured via Countermovement Jump test on a digital contact mat/force platform. Jump height is recorded in centimeters (cm), where higher values represent superior vertical jump capacity.
  • Reactive Strength Index (RSI) — Baseline (Pre-test) and 8 weeks (Post-test)
    Reactive strength capacity and neuromuscular stiffness assessed via Drop Jump (DJ) test from a 30 cm box. Calculated as jump height (meters) divided by ground contact time (seconds) \[RSI = Jump Height (m) / Contact Time (s)\]. Higher index scores reflect better reactive strength and shorter contact time.

Trial sites (1)

FacilityCityRegionStatus
Bitlis Eren University Bitlis Central
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07797920 on ClinicalTrials.gov ↗ ← All trials in Turkey